MX2022010925A - Compuestos para su uso en afecciones autoinmunitarias. - Google Patents

Compuestos para su uso en afecciones autoinmunitarias.

Info

Publication number
MX2022010925A
MX2022010925A MX2022010925A MX2022010925A MX2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A
Authority
MX
Mexico
Prior art keywords
compounds
autoimmune conditions
treatment
autoimmune
conditions
Prior art date
Application number
MX2022010925A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Sousa-Faro José María Fernández
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010925A publication Critical patent/MX2022010925A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de afecciones autoinmunitarias y en particular, para el tratamiento de la artritis reumatoide.
MX2022010925A 2020-03-02 2021-03-02 Compuestos para su uso en afecciones autoinmunitarias. MX2022010925A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382814 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055142 WO2021175829A1 (en) 2020-03-02 2021-03-02 Compounds for use in autoimmune conditions

Publications (1)

Publication Number Publication Date
MX2022010925A true MX2022010925A (es) 2022-09-29

Family

ID=74732952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010925A MX2022010925A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones autoinmunitarias.

Country Status (16)

Country Link
US (1) US20230158104A1 (es)
EP (1) EP4114432A1 (es)
JP (1) JP2023517537A (es)
KR (1) KR20220148896A (es)
CN (1) CN115867286A (es)
AU (1) AU2021229592A1 (es)
BR (1) BR112022017129A2 (es)
CA (1) CA3169557A1 (es)
CL (1) CL2022002397A1 (es)
CO (1) CO2022014023A2 (es)
IL (1) IL296070A (es)
MX (1) MX2022010925A (es)
PE (1) PE20231101A1 (es)
TW (1) TW202146039A (es)
UY (1) UY39111A (es)
WO (1) WO2021175829A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
TW202146039A (zh) 2021-12-16
BR112022017129A2 (pt) 2022-10-11
AU2021229592A1 (en) 2022-09-29
CO2022014023A2 (es) 2022-11-18
UY39111A (es) 2021-09-30
CL2022002397A1 (es) 2023-06-30
US20230158104A1 (en) 2023-05-25
WO2021175829A1 (en) 2021-09-10
JP2023517537A (ja) 2023-04-26
PE20231101A1 (es) 2023-07-18
CA3169557A1 (en) 2021-09-10
KR20220148896A (ko) 2022-11-07
CN115867286A (zh) 2023-03-28
EP4114432A1 (en) 2023-01-11
IL296070A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
PH12020551463A1 (en) Pd-1 agonist antibodies and uses thereof.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
MY201925A (en) Macrocyclic compounds and uses thereof
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
DK1814878T3 (da) Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
ZA202207804B (en) Compounds and uses thereof
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022009366A (es) Compuestos y usos de estos.
MX2022009367A (es) Compuestos y usos de estos.
MX2023005436A (es) Compuestos y usos de estos.
MX2022010925A (es) Compuestos para su uso en afecciones autoinmunitarias.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2019005621A (es) Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
MX2020006140A (es) Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
MX2019013785A (es) Metodos y tratamiento de trauma.
MX2022012722A (es) Composiciones reticuladas y su uso.